Brief Report: Response to Hepatitis A Virus Vaccine in HIV-Infected Patients Within a Retrospective, Multicentric Cohort: Facing Hepatitis A Outbreaks in the Clinical Practice

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 81; no. 1; p. e1
• Main Authors: Neukam, Karin, Delgado Fernández, Marcial, Hernández Quero, José, Rivero-Juárez, Antonio, Llaves-Flores, Silvia, Jiménez Oñate, Francisco, Gutiérrez-Valencia, Alicia, Espinosa, Nuria, Viciana, Pompeyo, López-Cortés, Luis F
• Format: Journal Article
• Language: English
• Published: United States 01.05.2019
• Subjects: Adolescent; Adult; Aged; Coinfection - prevention & control; Disease Outbreaks - prevention & control; Female; Hepatitis A - prevention & control; Hepatitis A Vaccines - administration & dosage; Hepatitis A Vaccines - therapeutic use; HIV Infections - complications; HIV Infections - virology; Humans; Male; Middle Aged; Retrospective Studies; Spain - epidemiology; Young Adult; Spain
• ISSN: 1944-7884
• DOI: 10.1097/QAI.0000000000001990

Various recent outbreaks of hepatitis A virus (HAV) have been described in men who have sex with men despite the availability of an effective vaccine. This study aimed to determine the current rates of seroconversion after receiving HAV vaccine (HAV-V) in HIV-infected patients under real-life conditions. Patients were selected from a Southern Spanish multicentric cohort of HIV-infected subjects. Retrospective analysis of all patients who received 2 doses (standard scheme) from April 2008 to May 2016 or from June 2016 to February 2018 facing an HAV outbreak with shortage of HAV-V, 1 single dose of HAV-V. Response to HAV-V was defined as positive anti-HAV IgG between 1 and 12 months after the last vaccination dose. A total of 522 patients were included, mainly men who have sex with men (86.2%). In the standard-dose group, 303/343 [88.3%; 95% confidence interval (CI): 84.5 to 91.5] patients showed seroconversion as compared with 149/179 (83.2%; 95% CI: 76.9 to 88.4) of the single-dose group (P = 0.107). Undetectable baseline HIV-RNA (adjusted odds ratio: 4.86; 95% CI: 1.86 to 12.75; P = 0.001) and a CD4 T-cell count ≥350/μL (adjusted odds ratio, 3.96; 95% CI: 1.26 to 12.49; P = 0.019) were independently associated with response to both regimens. A higher CD4/CD8 ratio was also associated with response after a single dose. HIV-infected patients should be encouraged to undergo HAV-V with 2 standard doses 6 months apart; a single dose achieves a high rate of seroconversion in those patients with favorable response factors and may be enough to limit future outbreaks in case of HAV-V shortage until supply is reestablished.